Browse by Hotbed/Location
Filter News
Found 534,191 articles
-
Janssen Pharmaceutical of Johnson & Johnson released new long-term data from the open-label period of its Phase III VOYAGE 1 clinical trial.
-
According to the report, the majority of the cuts will occur in the company’s Human Health Division and are expected to begin Jan. 3 and conclude Jan. 16, 2020.
-
BioSpace Movers & Shakers, Oct. 18
10/18/2019
Pharma, biotech and medtech companies strengthen their executive ranks and boards with this week's Movers & Shakers. -
Genentech’s Xofluza Approved for People at High Risk of Developing Flu-Related Complications
10/18/2019
Genentech’s flu medication Xofluza won a new indication for the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for less than 48 hours and are at high risk of flu-related complications. -
Plexium is focused on developing therapeutics that influence E3 ligases that can degrade proteins, even the undruggable ones. The company’s founder and chief executive officer Kandaswamy “Swamy” Vijayan, took time out to speak with BioSpace about the company and its technology platform, DELPHe.
-
As the first part of a six-part series describing the hottest careers in the biopharma industry, we discussed the rewarding career of genetic counselor. Now, let’s take a look at the high in demand biopharma careers of biostatistician and biometrician.
-
New research by researchers at the University of California Los Angeles into the role of astrocytes, star-shaped brain cells, in the disease, may lead to new treatment strategies.
-
A competitor, Invitae Corporation, presented a poster at the American Society of Human Genetics (ASHG) annual meeting that essentially accuses 23andMe’s tests of completing missing a cancer-causing DNA variant in some ethnic groups.
-
A new method of synthesizing molecule arrangements in medicine could change the way many drugs, including the PARP inhibitor Zejula, a treatment for ovarian cancer, are produced.
-
Sei Bello Plastic Surgeon in North Atlanta Adopts Sensus Healthcare's Groundbreaking Superficial Radiation Therapy for Keloid Treatment
10/18/2019
Sei Bello, a plastic surgery center in Lawrenceville, Ga., announced today its adoption of Sensus Healthcare's Superficial Radiation Therapy, or SRT, for the treatment of keloids, a type of raised scar that forms on an area of the skin that has healed from an injury, such as a C-section or ear piercing.
-
Intelerad and Zebra Medical Vision Join Forces to Accelerate AI Adoption Through Newly Released Intelerad’s Odyssey Workflow Solution and Announce Unparalleled Introductory Offer
10/18/2019
Intelerad Medical Systems™, a leader in enterprise workflow solutions, and Zebra Medical Vision, the deep learning medical imaging analytics company, announce a joint program leveraging Intelerad’s newly released Odyssey designed to encourage the adoption of artificial intelligence without the prohibitive costs usually associated with such programs.
-
Altavant Sciences to Present Data Supporting Once-Daily Dosing of Rodatristat Ethyl at CHEST 2019
10/18/2019
Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced that its scientific team will be presenting preclinical safety, pharmacokinetic and biomarker pharmacodynamic data at the American College of Chest Physicians' annual CHEST 2019 meeting being held October 19 - 23 in New Orleans, Louisiana.
-
Hot Topics Recap: Breast Cancer Awareness Month 2019
10/18/2019
Following are the latest Breast Cancer Awareness Month 2019 news releases and story ideas for reporters, bloggers and media outlets
-
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2019 Operating Results
10/18/2019
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 1, 2019 to discuss its third quarter operating results
-
Growth of Heart Defect Closure Devices Market to be Impacted by the Use of 3D Imaging in Heart Defect Closure Procedures | Technavio
10/18/2019
The report, heart defect closure devices market 2019-2023, has been added to Technavio's catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on product and geography for the forecast period 2019-2023.
-
Aetna Announces the 2019 Voices of Health Competition Winners
10/18/2019
Aetna, a CVS Health (NYSE: CVS) company, today announced the winners of the 2019 Voices of Health competition, a celebration of grassroots non-profit organizations across the country that are working to address social determinants of health in their communities.
-
Growth of Spasticity Treatment Market to Be Impacted by Advent of Neurostimulation Devices | Technavio
10/18/2019
The report, spasticity treatment market 2019-2023, has been added to Technavio's catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on type and geography for the forecast period 2019-2023.
-
CareCentrix Celebrates Women's Network Success in Advancing Employees' Professional Development
10/18/2019
CareCentrix, the leading provider of home-based, post-acute care solutions celebrates the success of its Women's Network, an employee resource group aimed at promoting the advancement and inclusion of women leaders within CareCentrix
-
Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
10/18/2019
Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the closing of its public offering of 9,324,324 shares of its common stock at a price to the public of $18.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,216,216 shares of common stock.
-
InMed Pharmaceuticals to Present at the BIO Investor Forum
10/18/2019
InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the BIO Investor Forum in San Francisco: